TechnologyBoard of DirectorsManagement + FoundersScientific Advisory BoardNewsroomContact Us
Seeking to Redefine What is Possible in the Treatment of CNS Disorders

Promentis Pharmaceuticals, Inc. is a pharmaceutical company developing novel compounds for the treatment of schizophrenia and other central nervous system disorders. Promentis’ drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other diseases.